Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KALA BIO, Inc. (NASDAQ: KALA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into KALA’s clinical-stage biopharmaceutical business focused on rare and severe eye diseases, its mesenchymal stem cell secretome (MSC-S) platform, and its evolving financial and strategic position.
Through KALA’s annual reports on Form 10-K and quarterly reports on Form 10-Q, investors can review information on research and development activities, pipeline programs such as KPI-012 and KPI-014, risk factors, liquidity and capital resources. Current Reports on Form 8-K highlight material events, including the CHASE Phase 2b trial results for KPI-012, decisions to cease development of KPI-012 and the MSC-S platform, workforce reductions, financing agreements, loan defaults and settlements with Oxford Finance LLC, and Nasdaq listing deficiency notices.
KALA’s filings also include transaction-related documents, such as the Securities Purchase Agreement for Series AA and Series AAA convertible preferred stock, the Convertible Loan Agreement with an investor, and the Oxford Loan Settlement Agreement. These records explain how the company has structured recent financings, addressed debt obligations and framed its exploration of strategic alternatives. Notifications like Form 12b-25 describe timing of periodic reports when delays occur.
On Stock Titan, KALA filings are updated in near real time as they appear on EDGAR. AI-powered summaries help interpret lengthy 10-K and 10-Q reports, breaking down key sections on clinical programs, cash runway, going-concern language and risk disclosures. For Form 4 and other insider-related filings, users can quickly see reported insider transactions in KALA stock. This combination of raw filings and AI-generated explanations allows readers to understand what each document means for KALA’s business, capital structure and potential strategic direction without having to parse every page manually.
David E. Lazar has filed a Schedule 13D reporting a 5.18% beneficial ownership stake in KALA BIO, Inc., tied to preferred stock that is convertible into 49,500,000 shares of common stock. This stake is based on 954,749,725 shares outstanding as of February 6, 2026.
Lazar acquired 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock for
Under that agreement, Lazar was appointed Chief Executive Officer and a director effective November 23, 2025, with the right to recommend up to eight director nominees for stockholder election and to serve as Chairman upon his election. On February 2, 2026, he resigned as Chief Executive Officer but remains on the Board of Directors.
KALA BIO, Inc. reported a leadership change effective February 2, 2026. David Lazar resigned as both Chief Executive Officer and Chief Financial Officer on that date but remains a member of the board of directors.
To fill these roles, the board appointed existing director Avi Minkowitz as the new Chief Executive Officer and Chief Financial Officer, effective the same day. The company highlights his background in investment, mergers and acquisitions, real estate, and management consulting, as well as prior board and entrepreneurial experience. The filing notes there are no disclosable family relationships or related-party transactions involving Mr. Minkowitz under the cited SEC regulations.
KALA BIO, INC. closed the second part of a private preferred stock financing and reshaped its governance structure. The company sold 2,100,000 shares of Series AAA preferred stock at $2.00 per share for gross proceeds of $4.2 million, with each share convertible into 420 common shares, or 882,000,000 common shares in total. This follows a prior sale of 900,000 Series AA preferred shares for $1.8 million, convertible into 49,500,000 common shares. Stockholders approved issuing common shares upon conversion of both series, authorized increasing common stock to 1,500,000,000 shares, and approved a potential reverse split at a ratio between 1‑for‑2 and 1‑for‑100. Six incumbent directors resigned tied to these approvals, and five nominees associated with AK Holdings were appointed to the board, resulting in a significant change in board composition and control.
KALA BIO, Inc. reported that it received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement of
The company has a 180-day compliance period, until
The notice does not immediately affect the listing or trading of KALA’s common stock, but failure to regain compliance could lead to delisting, subject to potential appeal.
LifeSci Capital LLC reported beneficial ownership of 2,200,000 shares of KALA BIO, Inc. common stock, representing 7.9% of the outstanding class. The percentage is based on 27,849,725 shares of common stock outstanding as of December 31, 2025, as referenced from a company prospectus.
LifeSci Capital has sole voting and dispositive power over these shares. Andrew McDonald and Michael Rice are listed as reporting persons with shared voting and dispositive power over the same 2,200,000 shares through LifeSci Capital, but each disclaims beneficial ownership except for any pecuniary interest. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of KALA BIO.
KALA BIO, Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC that allows the company to sell up to $15,000,000 of its common stock under an existing shelf registration statement on Form S-3. Sales, if any, will be made from time to time through or to H.C. Wainwright as sales agent or principal, generally at the prevailing market price of the stock on the Nasdaq Capital Market.
The company controls key parameters for each sale, including the number of shares, timing, daily limits, and minimum acceptable price, and has no obligation to sell any shares. H.C. Wainwright will earn a commission of 3.0% of the gross sales price on shares it sells, and the company will reimburse specified legal and due diligence expenses. Either party can suspend offers under the agreement, and there is no assurance that any shares will ultimately be sold.
KALA BIO, Inc. is establishing an at-the-market program to sell up to $15,000,000 of common stock through H.C. Wainwright & Co. Shares may be sold from time to time on Nasdaq or other U.S. markets, with Wainwright earning a 3.0% commission on gross proceeds. At an assumed price of $0.6211 per share, this would equal about 24.2 million shares, bringing total common stock outstanding to 52,000,425 shares, though actual amounts may differ.
The company plans to use net proceeds for general corporate purposes and working capital, but 25% of new debt or equity financings must be used to repay a 15% convertible loan, and 10% of equity proceeds after a shareholder meeting must be paid to Oxford up to $1,000,000. Recent financings include a December 2025 $10 million registered direct equity raise and a November 2025 preferred stock private placement of up to $6.0 million. The filing highlights substantial doubt about the company’s ability to continue as a going concern, a Nasdaq market value deficiency notice, and significant additional dilution potential from options, warrants, RSUs and convertible preferred stock.
KALA BIO dismissed Deloitte & Touche LLP as its independent registered public accounting firm effective December 15, 2025. Deloitte had audited the company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023.
The company states that Deloitte’s prior audit reports did not include adverse or disclaimed opinions and were not qualified or modified for uncertainty, scope, or principles. KALA BIO reports no disagreements with Deloitte and no reportable events during those periods and through December 15, 2025. The company has not yet appointed a new independent auditor.
KALA BIO has scheduled its next annual meeting of stockholders for January 30, 2026, and set December 27, 2025 as the deadline for shareholder proposals and director nominations under its bylaws and SEC Rule 14a-8.
The company reiterates financing arrangements with CEO David Lazar, including a $375,000 convertible loan and a private placement of preferred stock for aggregate gross proceeds of up to $6.0 million, of which $1.8 million has been received from the sale of 900,000 Series AA preferred shares at $2.00 per share.
Lazar has contracted to sell his rights and obligations to purchase the Series AAA preferred shares, and related purchase agreement rights, to unaffiliated investor AK Holdings Group Inc., while retaining his Series AA preferred shares and the convertible loan. A principal of AK Holdings has been engaged as a consultant to help the company identify and consummate a strategic alternative transaction, which, along with the potential Series AAA closing and related stockholder approvals, is subject to the uncertainties highlighted in the company’s forward-looking statements.
KALA BIO, Inc. disclosed that Chief Executive Officer and director David E. Lazar entered into a securities purchase agreement to invest in the company through convertible preferred stock. On November 24, 2025, he acquired 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock at $2.00 per share, for a total of $1,800,0002,100,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share, for an additional $4,200,000.
Each share of Series AA Preferred is convertible into 55 shares of common stock and each Series AAA share into 420 shares, in both cases subject to ownership limits. None of the preferred shares can be converted until stockholders approve an increase in authorized capital and the conversion terms in line with Nasdaq listing rules. The Series AA Preferred Stock is perpetual and has no expiration date, and Lazar reports no common stock currently beneficially owned.